156 related articles for article (PubMed ID: 10721092)
21. Pathogenesis of L-tryptophan eosinophilia myalgia syndrome.
Sternberg EM
Adv Exp Med Biol; 1996; 398():325-30. PubMed ID: 8906284
[TBL] [Abstract][Full Text] [Related]
22. The natural history of eosinophilia-myalgia syndrome in a tryptophan-exposed cohort in South Carolina.
Sullivan EA; Kamb ML; Jones JL; Meyer P; Philen RM; Falk H; Sinks T
Arch Intern Med; 1996 May; 156(9):973-9. PubMed ID: 8624177
[TBL] [Abstract][Full Text] [Related]
23. Eosinophilia-myalgia syndrome associated with L-tryptophan. A case report with pulmonary manifestations and review of the literature.
André M; Canon JL; Levecque P; Dermine P; Mortier C; Leveau F
Acta Clin Belg; 1991; 46(3):178-82. PubMed ID: 1656679
[TBL] [Abstract][Full Text] [Related]
24. Eosinophil-active cytokine from mononuclear cells cultured with L-tryptophan products: an unexpected consequence of endotoxin contamination.
Kita H; Mayeno AN; Weyand CM; Goronzy JJ; Weiler DA; Lundy SK; Abrams JS; Gleich GJ
J Allergy Clin Immunol; 1995 Jun; 95(6):1261-7. PubMed ID: 7797795
[TBL] [Abstract][Full Text] [Related]
25. L-tryptophan-related eosinophilia-myalgia syndrome possibly associated with a chronic B-lymphocytic leukemia.
Böhme A; Wolter M; Hoelzer D
Ann Hematol; 1998 Nov; 77(5):235-8. PubMed ID: 9858150
[TBL] [Abstract][Full Text] [Related]
26. Eosinophilia myalgia syndrome: absence of immunoglobulin reactivity suggests a cellular rather than humoral mechanism.
Villanova M; De Clerck LS; Cras P; Guazzi GC; Martin JJ
Acta Neurol Belg; 1994; 94(3):200-4. PubMed ID: 7976226
[TBL] [Abstract][Full Text] [Related]
27. A decomposition product of a contaminant implicated in L-tryptophan eosinophilia myalgia syndrome affects spinal cord neuronal cell death and survival through stereospecific, maturation and partly interleukin-1-dependent mechanisms.
Brenneman DE; Page SW; Schultzberg M; Thomas FS; Zelazowski P; Burnet P; Avidor R; Sternberg EM
J Pharmacol Exp Ther; 1993 Aug; 266(2):1029-35. PubMed ID: 8355179
[TBL] [Abstract][Full Text] [Related]
28. Review of L-tryptophan and eosinophilia-myalgia syndrome.
Roufs JB
J Am Diet Assoc; 1992 Jul; 92(7):844-50. PubMed ID: 1624654
[TBL] [Abstract][Full Text] [Related]
29. Production of polyclonal antibodies against 1,1'-ethyliden bis[L-tryptophan] (EBT), a potential contaminant causing eosinophilia-myalgia syndrome (EMS).
Kurihara N; Yanagisawa H; Jin Z; Wada O
Toxicol Lett; 1993 Mar; 66(3):231-6. PubMed ID: 8475503
[TBL] [Abstract][Full Text] [Related]
30. Chronic demyelinating polyneuropathy associated with eosinophilia-myalgia syndrome.
Freimer ML; Glass JD; Chaudhry V; Tyor WR; Cornblath DR; Griffin JW; Kuncl RW
J Neurol Neurosurg Psychiatry; 1992 May; 55(5):352-8. PubMed ID: 1534836
[TBL] [Abstract][Full Text] [Related]
31. Demyelinating polyneuropathy in eosinophilia-myalgia syndrome.
Donofrio PD; Stanton C; Miller VS; Oestreich L; Lefkowitz DS; Walker FO; Ely EW
Muscle Nerve; 1992 Jul; 15(7):796-805. PubMed ID: 1323757
[TBL] [Abstract][Full Text] [Related]
32. [A case of the eosinophilia-myalgia syndrome].
Ishikawa A; Akahosi T; Okada J; Kondo H; Kasiwazaki S
Ryumachi; 1992 Aug; 32(4):327-30; discussion 330-2. PubMed ID: 1411794
[TBL] [Abstract][Full Text] [Related]
33. Epidemiologic studies of the association of L-tryptophan with the eosinophilia-myalgia syndrome: a critique.
Shapiro S
J Rheumatol Suppl; 1996 Oct; 46():44-58; discussion 58-9. PubMed ID: 8895181
[TBL] [Abstract][Full Text] [Related]
34. Detection of antineutrophil cytoplasmic antibody in a patient with L-tryptophan induced eosinophilia-myalgia syndrome.
Cilursu AM; Goeken J; Olson RR
Ann Rheum Dis; 1991 Nov; 50(11):817-9. PubMed ID: 1772299
[TBL] [Abstract][Full Text] [Related]
35. Enhanced collagen synthesis and transcription by peak E, a contaminant of L-tryptophan preparations associated with the eosinophilia myalgia syndrome epidemic.
Takagi H; Ochoa MS; Zhou L; Helfman T; Murata H; Falanga V
J Clin Invest; 1995 Nov; 96(5):2120-5. PubMed ID: 7593596
[TBL] [Abstract][Full Text] [Related]
36. Eosinophilia myalgia syndrome.
Blackburn WD
Semin Arthritis Rheum; 1997 Jun; 26(6):788-93. PubMed ID: 9213377
[TBL] [Abstract][Full Text] [Related]
37. Structural characterization of contaminants found in commercial preparations of melatonin: similarities to case-related compounds from L-tryptophan associated with eosinophilia-myalgia syndrome.
Williamson BL; Tomlinson AJ; Mishra PK; Gleich GJ; Naylor S
Chem Res Toxicol; 1998 Mar; 11(3):234-40. PubMed ID: 9544622
[TBL] [Abstract][Full Text] [Related]
38. Eosinophilia-myalgia syndrome in L-tryptophan-exposed patients.
Kamb ML; Murphy JJ; Jones JL; Caston JC; Nederlof K; Horney LF; Swygert LA; Falk H; Kilbourne EM
JAMA; 1992 Jan; 267(1):77-82. PubMed ID: 1727200
[TBL] [Abstract][Full Text] [Related]
39. Chronic immune activation in the eosinophilia-myalgia syndrome.
McKinley KL; Harati Y; Schneider LW
Muscle Nerve; 1993 Sep; 16(9):947-51. PubMed ID: 8355725
[TBL] [Abstract][Full Text] [Related]
40. Persistent microvasculopathy in chronic eosinophilia-myalgia syndrome.
Smith SA
Adv Exp Med Biol; 1996; 398():359-64. PubMed ID: 8906289
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
